Single ascending dose phase Ib trial investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of BGB 324 in healthy volunteers

Trial Profile

Single ascending dose phase Ib trial investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of BGB 324 in healthy volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Apr 2014

At a glance

  • Drugs BGB 324 (Primary)
  • Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Non-small cell lung cancer
  • Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacokinetics
  • Sponsors BerGenBio
  • Most Recent Events

    • 09 Apr 2014 Status changed from recruiting to completed.
    • 09 Apr 2014 Results were presented at the Annual Meeting of the American Association of Cancer Research (AACR) in April 2014.
    • 05 Feb 2014 Results are expected in 2015 according to a BerGenBio media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top